The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas

Recent studies have shown that the efficacy of PARP inhibitors in epithelial ovarian carcinoma (EOC) is related to tumor-specific defects in homologous recombination (HR) and extends beyond <i>BRCA1/2</i> deficient EOC. A robust method with which to identify HR-deficient (HRD) carcinomas...

Full description

Bibliographic Details
Main Authors: Lise M. van Wijk, Sylvia Vermeulen, Matty Meijers, Manuela F. van Diest, Natalja T. ter Haar, Marthe M. de Jonge, Nienke Solleveld-Westerink, Tom van Wezel, Dik C. van Gent, Judith R. Kroep, Tjalling Bosse, Katja N. Gaarenstroom, Harry Vrieling, Maaike P. G. Vreeswijk
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
epithelial ovarian carcinoma
homologous recombination deficiency
RECAP test
RAD51
BRCA1
BRCA2
Online Access:https://www.mdpi.com/2072-6694/12/10/2805

Internet

https://www.mdpi.com/2072-6694/12/10/2805

Similar Items